Svetomir N. Markovic

1 month ago | nature.com | Jacob J. Orme |Robert McWilliams |Robert Mcwilliams |Matthew Block |Aaron Mansfield |Svetomir N. Markovic | +3 more

AbstractImmune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge.